Since OSM is an interleukin-6 (IL-6) type cytokine to inhibit melanoma proliferation, the loss of OSM gene expression in drug-resistant patients may inhibit the activity of collagen biosynthesis and interleukin-6 family signaling. Here, IL6 is linked to melanoma.